Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when BIAF files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsbioAffinity stockholders approve 15x equity plan expansion and authorize reverse stock split
Filed April 30, 2026 · Period ending April 30, 2026 · ~1 min read
Key Changes
-
high
Stockholders approved expanding the 2024 Equity Incentive Plan from 66,666 to 1,000,000 shares, a 15-fold increase that significantly expands management's ability to grant stock-based compensation and will dilute existing shareholders when awards are issued.
Item 5.07 verify on EDGAR → -
high
Authorized reverse stock split at ratio between 1-for-2 and 1-for-250, with exact ratio at board's discretion. Typically used to maintain exchange listing requirements by boosting per-share price while reducing share count.
Item 5.07 verify on EDGAR → -
high
Approved issuance of up to 637,120 shares from warrant exercises and anti-dilution adjustments tied to August 2025 financing and Series B Preferred stock, representing substantial potential dilution from existing instruments.
Item 5.07 verify on EDGAR → -
medium
Granted management broad authorization to conduct future private placements under Nasdaq rules without returning to shareholders for approval, including potential change-of-control scenarios.
Item 5.07 verify on EDGAR → -
low
All six director nominees re-elected to serve until 2027 annual meeting with no changes to board composition.
Item 5.07 verify on EDGAR →
Summary
bioAffinity Technologies stockholders approved a package of proposals at the 2026 Annual Meeting that substantially expands management's financial flexibility while creating significant dilution risk for existing shareholders.
The centerpiece is a 15-fold expansion of the equity compensation plan and authorization for a reverse stock split at ratios up to 1-for-250, suggesting potential concerns about maintaining Nasdaq listing requirements. The approved measures authorize issuance of over 637,000 shares from existing warrant exercises and anti-dilution adjustments, plus 1 million shares for future equity grants.
Combined with blanket authorization for future private placements, these approvals give management broad latitude to raise capital and compensate employees, but at the cost of substantial shareholder dilution. The wide range on the reverse split ratio (up to 250-to-1) is unusually broad and may signal uncertainty about the company's stock price trajectory. Investors should monitor whether and at what ratio the board executes the reverse split, as this will signal management's assessment of listing compliance risk. Watch for announcements of equity grants under the expanded plan and any new private placements, both of which will immediately dilute your ownership stake.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
bioAffinity stockholders approved 10 proposals including warrant exercises, anti-dilution adjustments, equity plan expansion, and reverse stock split.
Added in current filing · verify on EDGAR →
The stockholders approved the issuance of up to an aggregate of 271,500 shares of Common Stock upon the exercise of (i) 223,831 shares of Common Stock issuable upon exercise of Common Stock purchase warrants issued in connection with the private placement offering that closed on August 14, 2025 (the “August 2025 Common Warrants”), (ii) 47,669 shares of Common Stock issuable upon exercise of Common Stock purchase warrants issued in connection with the warrant inducement transaction that closed on August 14, 2025 (the “August 2025 Inducement Warrants”, together the August 2025 Common Warrants and the Inducement Warrants, the “August 2025 Warrants”), respectively, that may be equal to or exceed 20% of Common Stock outstanding before such offering.
Stockholders approved issuance of up to 271,500 shares from August 2025 warrant exercises and up to 365,620 additional shares from anti-dilution adjustments to those warrants. Combined with Series B Preferred anti-dilution adjustments (131,884 shares), these approvals authorize substantial potential dilution from existing financing instruments.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The stockholders elected each of the six director nominees to serve on the Company’s board of directors until the 2027 Annual Meeting of Stockholders and until such director’s successor has been duly elected and qualified.
All six director nominees (Maria Zannes, Steven Girgenti, Peter Knight, Jamie Platt, Roberto Rios, and John Oppenheimer) were elected to serve until the 2027 annual meeting. This represents routine board continuity with no changes to board composition.
Event · Item 9.01 — Financial Statements and Exhibits
bioAffinity Technologies filed an 8-K to disclose a First Amendment to its 2024 Incentive Compensation Plan.
Added in current filing · verify on EDGAR →
First Amendment to bioAffinity Technologies, Inc. 2024 Incentive Compensation Plan
The company has amended its 2024 Incentive Compensation Plan. The 8-K does not provide details on the nature of the amendment, such as changes to share reserves, eligibility, or award terms. Investors should review the full exhibit to understand the specific modifications to the equity compensation framework.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify